Description
Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia are highly prevalent gastrointestinal disorders worldwide. These conditions often coexist, making clinical differentiation difficult.
- The global prevalence of GERD is around 99%, and Functional Dyspepsia affects 20–30% of the general population.
- Proton Pump Inhibitors (PPIs), alone or combined with prokinetic agents, are proven effective in relieving symptoms and improving quality of life in acid-related disorders.
ESOBRICK-D
Composition: Esomeprazole EC 40 mg + Domperidone SR 30 mg Capsule
Indications
- GERD (Gastroesophageal Reflux Disease)
- NAB (Nocturnal Acid Breakthrough)
- Diabetic Gastroparesis
- Functional Dyspepsia
- Gastritis
- Acid Peptic Disorders
Mechanism of Action
Esomeprazole:
A selective proton pump inhibitor (PPI) that blocks the H⁺/K⁺ ATPase enzyme in gastric parietal cells, leading to effective suppression of gastric acid secretion.
Domperidone:
A dopamine D₂ and D₃ receptor antagonist that enhances gastric emptying, increases lower esophageal sphincter (LES) tone, and reduces gastrointestinal transit time. It does not cross the blood-brain barrier, minimizing CNS side effects.
Key Features
- Rapid pH Control: Esomeprazole maintains intragastric pH >4 longer than other PPIs.
- Safe Prokinetic Options: Domperidone avoid significant CNS or cardiovascular effects.
- Dual Action: Combination therapy provides both acid suppression and motility enhancement.
Presentation
- ESOBRICK- D Alu-Alu Strip of 10 capsules
Reviews
There are no reviews yet.